Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPG NASDAQ:AGIO NASDAQ:CCCC NASDAQ:TSHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$17.07-0.3%$22.53$16.92▼$48.45$1.60B-0.0510,607 shs2,569 shsAGIOAgios Pharmaceuticals$28.14+2.6%$29.55$22.24▼$46.00$1.63B0.59744,832 shs1.29 million shsCCCCC4 Therapeutics$3.58-0.3%$3.20$1.36▼$4.60$396.94M2.922.91 million shs1.65 million shsTSHATaysha Gene Therapies$5.36-1.3%$5.70$2.25▼$7.30$1.56B1.192.13 million shs4.31 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International-0.29%-7.48%-20.60%-29.52%-42.87%AGIOAgios Pharmaceuticals+2.55%+6.15%+1.26%+0.25%-16.40%CCCCC4 Therapeutics-0.28%-17.51%+21.36%+19.73%+113.10%TSHATaysha Gene Therapies-1.29%-5.80%-21.29%+18.85%+91.43%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$17.07-0.3%$22.53$16.92▼$48.45$1.60B-0.0510,607 shs2,569 shsAGIOAgios Pharmaceuticals$28.14+2.6%$29.55$22.24▼$46.00$1.63B0.59744,832 shs1.29 million shsCCCCC4 Therapeutics$3.58-0.3%$3.20$1.36▼$4.60$396.94M2.922.91 million shs1.65 million shsTSHATaysha Gene Therapies$5.36-1.3%$5.70$2.25▼$7.30$1.56B1.192.13 million shs4.31 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International-0.29%-7.48%-20.60%-29.52%-42.87%AGIOAgios Pharmaceuticals+2.55%+6.15%+1.26%+0.25%-16.40%CCCCC4 Therapeutics-0.28%-17.51%+21.36%+19.73%+113.10%TSHATaysha Gene Therapies-1.29%-5.80%-21.29%+18.85%+91.43%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.25Buy$46.67173.38% UpsideAGIOAgios Pharmaceuticals 2.45Hold$41.4447.28% UpsideCCCCC4 Therapeutics 2.57Moderate Buy$7.75116.48% UpsideTSHATaysha Gene Therapies 3.00Buy$11.64117.10% UpsideCurrent Analyst Ratings BreakdownLatest CCCC, AGIO, TSHA, and AAPG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026AGIOAgios Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$41.00 ➝ $40.004/30/2026AGIOAgios Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$39.00 ➝ $36.004/24/2026AAPGAscentage Pharma Group International Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.004/21/2026AGIOAgios Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$44.00 ➝ $41.004/20/2026CCCCC4 Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026AGIOAgios Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$65.00 ➝ $50.004/13/2026AAPGAscentage Pharma Group International BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$48.004/6/2026AAPGAscentage Pharma Group InternationalChina Intl CapSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/6/2026AGIOAgios Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$31.00 ➝ $36.004/6/2026TSHATaysha Gene Therapies Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $17.004/1/2026AGIOAgios Pharmaceuticals The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$28.00 ➝ $32.00(Data available from 6/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$82.10M19.40N/AN/A$2.04 per share8.37AGIOAgios Pharmaceuticals$54.03M30.97N/AN/A$20.46 per share1.38CCCCC4 Therapeutics$35.95M11.01N/AN/A$2.65 per share1.35TSHATaysha Gene Therapies$9.77M157.65N/AN/A$0.90 per share5.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group International-$177.71MN/AN/AN/AN/AN/AN/AN/AN/AAGIOAgios Pharmaceuticals-$412.78M-$7.25N/AN/AN/A-639.84%-34.11%-31.66%7/30/2026 (Estimated)CCCCC4 Therapeutics-$104.99M-$1.19N/AN/AN/A-297.76%-50.68%-33.22%8/6/2026 (Estimated)TSHATaysha Gene Therapies-$109M-$0.38N/AN/AN/AN/A-56.07%-40.16%8/11/2026 (Estimated)Latest CCCC, AGIO, TSHA, and AAPG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026CCCCC4 Therapeutics-$0.2506-$0.20+$0.0506-$0.20$4.42 million$6.15 million5/6/2026Q1 2026TSHATaysha Gene Therapies-$0.10-$0.12-$0.02-$0.12$0.76 millionN/A4/29/2026Q1 2026AGIOAgios Pharmaceuticals-$1.81-$1.69+$0.12-$1.69$13.30 million$20.75 million3/25/2026H2 2025AAPGAscentage Pharma Group InternationalN/A-$0.5150N/A-$0.5150N/A$24.72 million3/19/2026Q4 2025TSHATaysha Gene Therapies-$0.11-$0.08+$0.03-$0.08$1.89 million$5.49 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/ACCCCC4 TherapeuticsN/AN/AN/AN/AN/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group International0.571.791.77AGIOAgios PharmaceuticalsN/A14.1913.59CCCCC4 TherapeuticsN/A9.009.00TSHATaysha Gene Therapies0.2314.0414.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/AAGIOAgios PharmaceuticalsN/ACCCCC4 Therapeutics78.81%TSHATaysha Gene Therapies77.70%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/AAGIOAgios Pharmaceuticals5.40%CCCCC4 Therapeutics5.60%TSHATaysha Gene Therapies3.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60093.33 millionN/AN/AAGIOAgios Pharmaceuticals39059.47 million56.26 millionOptionableCCCCC4 Therapeutics150110.57 million104.38 millionOptionableTSHATaysha Gene Therapies180287.36 million276.50 millionOptionableCCCC, AGIO, TSHA, and AAPG HeadlinesRecent News About These CompaniesTaysha Gene Therapies Grants Restricted Stock Units and Stock Options to New EmployeesJune 5, 2026 | quiverquant.comQTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 5, 2026 | globenewswire.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Recommendation of "Buy" by BrokeragesJune 4, 2026 | americanbankingnews.comTaysha Gene Therapies Shareholders Back Governance and LeadershipJune 2, 2026 | tipranks.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (BMY), Corcept Therapeutics (CORT) and Taysha Gene Therapies (TSHA)June 2, 2026 | theglobeandmail.comTaysha Gene Therapies: Shortened Timeline Increases The PotentialJune 1, 2026 | seekingalpha.comASPIRE Rett Syndrome Trial Puts Taysha’s TSHA-102 Gene Therapy in Focus for InvestorsMay 22, 2026 | tipranks.comNeedham ups Taysha target on ‘derisking’ TSHA-102 newsMay 15, 2026 | msn.comTaysha Gene Therapies (TSHA) Reports Financial Results for Q1 2026May 14, 2026 | finance.yahoo.comCanaccord Keeps Buy Rating on Taysha (TSHA) After Q1 HighlightsMay 11, 2026 | insidermonkey.comTaysha Gene Therapies Ramps Up Ahead of TSHA-102 BLAMay 10, 2026 | tipranks.comAssessing Taysha Gene Therapies (TSHA) Valuation After Strong Momentum And Recent VolatilityMay 9, 2026 | finance.yahoo.comTaysha Gene Therapies, Inc. Q1 2026 Earnings Call SummaryMay 9, 2026 | finance.yahoo.comTaysha outlines PPQ completion by Q4 2026 while targeting a TSHA-102 BLA option based on a 6-month interim analysisMay 7, 2026 | seekingalpha.comTaysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 6, 2026 | globenewswire.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | globenewswire.comTaysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6April 29, 2026 | globenewswire.comHas Taysha Gene Therapies (TSHA) Run Too Far After A 259% One Year Surge?April 28, 2026 | finance.yahoo.comTaysha Gene Therapies Reports Preclinical Data Supporting TSHA-102 Gene Therapy for Rett Syndrome at ASGCT Annual MeetingApril 27, 2026 | quiverquant.comQTaysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual MeetingApril 27, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCCCC, AGIO, TSHA, and AAPG Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$17.07 -0.05 (-0.29%) Closing price 06/9/2026 03:49 PM EasternExtended Trading$17.04 -0.04 (-0.21%) As of 06/9/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.Agios Pharmaceuticals NASDAQ:AGIO$28.14 +0.70 (+2.55%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$27.71 -0.43 (-1.53%) As of 06/9/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.C4 Therapeutics NASDAQ:CCCC$3.58 -0.01 (-0.28%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$3.59 +0.01 (+0.36%) As of 04:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Taysha Gene Therapies NASDAQ:TSHA$5.36 -0.07 (-1.29%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$5.40 +0.04 (+0.73%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Corning Is Paving AI's Future With Glass The J.M. Smucker Company’s Dividend: Too Sweet to Ignore? Why's Amazon Suddenly Lagging the S&P 500, and Is It a Warning? Apple's Siri AI Was Finally Announced, So Why Is the Stock Tanking? From Crypto to AI: Insiders Are Trading These 3 Stocks The Case for Intel Over Pure-Play Quantum Firms Has Temu-Owner PDD's Story Changed After Double Miss? Campbell's Soup Stock: Deep Value and a 7% Dividend Yield Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
